PMID- 35666484
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220608
IS  - 1551-7489 (Print)
IS  - 1551-7489 (Linking)
VI  - 18
IP  - 3
DP  - 2022 May-Jun
TI  - Clinical role and safety of tapentadol in patients with cancer: A single-center 
      experience.
PG  - 273-280
LID - jom.2022.0719 [pii]
LID - 10.5055/jom.2022.0719 [doi]
AB  - OBJECTIVE: To evaluate real-world data on the use of tapentadol (TAP) in cancer 
      patients. DESIGN: Single-center retrospective study. SETTING: 
      Curative/palliative. PATIENTS, PARTICIPANTS: Patients who started TAP between 
      October 2014 and December 2018 at our institution. MAIN OUTCOME MEASURE(S): The 
      primary outcome was the reason for TAP initiation. Secondary outcomes included 
      prescription duration, TAP cessation rate, reason for cessation, and adverse 
      events (AEs). Since the palliative care team (PCT) tended to prescribe to cancer 
      patients with intractable pain more often than patients in usual care, and also 
      tended to prescribe opioids based on their characteristics, we decided to compare 
      patients with and without PCT intervention. RESULTS: There were 175 patients who 
      first received TAP during the study period, of whom 81 patients (46.3 percent) 
      were male. The median age was 60 years. TAP was prescribed for opioid-naive 
      patients in 45 (26 percent) cases and opioid switch in 130 (74 percent) cases. 
      When comparing the PCT group (n = 121) and the non-PCT group (n = 54) using 
      univariate analysis, the PCT group had a higher opioid switch rate (81.8 percent 
      vs 57.4 percent, p < .001), higher proportion of patients with neuropathic pain 
      (NP) (65.3 percent vs 16.7 percent, p < .001), and a higher proportion of 
      patients with a history of nausea (41.3 percent vs 18.5 percent, p < .01). The 
      cessation rate due to AEs was 8 percent overall. CONCLUSIONS: Palliative care 
      physicians prescribed TAP for patients with NP or a history of nausea. 
      Opioid-naive patients were preferred by oncologists. TAP has good tolerability in 
      both groups, with a low dropout rate due to AEs.
FAU - Kubo, Emi
AU  - Kubo E
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan. 
      ORCID: https://orcid.org/0000-0001-9369-2824.
FAU - Ishiki, Hiroto
AU  - Ishiki H
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan. 
      ORCID: https://orcid.org/0000-0002-0800-2161.
FAU - Abe, Kentaro
AU  - Abe K
AD  - Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
FAU - Kaku, Sawako
AU  - Kaku S
AD  - Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, 
      Japan.
FAU - Yokota, Sayuri
AU  - Yokota S
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Arakawa, Sayaka
AU  - Arakawa S
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Kiuchi, Daisuke
AU  - Kiuchi D
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Amano, Koji
AU  - Amano K
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Satomi, Eriko
AU  - Satomi E
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Opioid Manag
JT  - Journal of opioid management
JID - 101234523
RN  - 0 (Analgesics, Opioid)
RN  - H8A007M585 (Tapentadol)
SB  - IM
MH  - *Analgesics, Opioid/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced/complications
MH  - *Neoplasms/complications
MH  - Retrospective Studies
MH  - Tapentadol
EDAT- 2022/06/07 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/06/06 15:38
PHST- 2022/06/06 15:38 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
AID - jom.2022.0719 [pii]
AID - 10.5055/jom.2022.0719 [doi]
PST - ppublish
SO  - J Opioid Manag. 2022 May-Jun;18(3):273-280. doi: 10.5055/jom.2022.0719.